We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+15.33%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$280M
AUM Growth
+$15.1M
Cap. Flow
-$14.8M
Cap. Flow %
-5.28%
Top 10 Hldgs %
70.61%
Holding
30
New
4
Increased
13
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$18.2M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$14M
3
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M
4
SLN
Silence Therapeutics
SLN
+$8.95M
5
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.93M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$21.3M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$19.1M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.8M
4
KALV
KalVista Pharmaceuticals
KALV
+$7.19M
5
FOLD
Amicus Therapeutics
FOLD
+$7.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
26
AnaptysBio
ANAB
$1.68B
– –
-249,609
Closed -$6.26M
ELVN icon
27
Enliven Therapeutics
ELVN
$4.43B
– –
-152,178
Closed -$3.56M
FOLD
28
DELISTED
Amicus Therapeutics
FOLD
– –
-713,536
Closed -$7.08M
RAPP
29
Rapport Therapeutics
RAPP
$2.18B
– –
-70,000
Closed -$1.63M
MORF
30
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-47,660
Closed -$1.62M
1
2

Similar funds

TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.32% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
BCM
Bienville Capital Management New York $550M AUM 3.49% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $549M AUM 24.44% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Saturn V Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Saturn V Capital Management held 30 positions worth $280M, up 5.7% from $265M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Saturn V Capital Management withdrew a net $14.8M in Q3 2024, closing 5 positions and reducing 8 holdings. Its most notable exit was Amicus Therapeutics, an estimated $7.08M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Saturn V Capital Management opened a new position in CG Oncology worth $19.6M.

  • Saturn V Capital Management's largest Q3 2024 buy was CG Oncology: 520,119 shares worth $19.6M.
  • Saturn V Capital Management added most to Ascendis Pharma A/S in Q3 2024, an estimated $11.8M increase.
  • Saturn V Capital Management's biggest Q3 2024 reduction was argenx, cutting an estimated $21.3M.
  • Saturn V Capital Management fully exited Amicus Therapeutics in Q3 2024, selling an estimated $7.08M.
  • Saturn V Capital Management's ten largest holdings make up 71% of its $280M portfolio in Q3 2024.
  • Saturn V Capital Management opened 4 new positions and closed 5 in Q3 2024.
  • Saturn V Capital Management's portfolio value rose 5.7% quarter-over-quarter to $280M.

Based on Saturn V Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.